AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 83 min read$ANGO

AngioDynamics, Inc. Q1 2027 Earnings Call Summary

AngioDynamics reported Q1 2027 earnings, with MedTech segment revenue growing 13.2% YoY, now 49% of total revenue. Auryon saw 21st straight quarter of double-digit growth. NanoKnife adoption increased, with record procedure volumes. Full-year revenue guidance is $336M-$341M, with MedTech expected to dominate. Gross margin expanded 410 bps due to pricing and mix shift. Eric Honer appointed as new CEO. The company remains debt-free and expects positive cash flow for the year.

Original reporting
finance.yahoo.com
Published Oct 8, 2026, 4:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 5:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AngioDynamics, Inc. Q1 2027 Earnings Call Summary — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ANGONeutralHigh
01

Why it matters

The earnings call outlines growth drivers, FDA approvals, and strategic initiatives that shape near-term valuation.

02

Market read

First-report earnings guidance for AngioDynamics provides actionable data for traders focusing on medtech equities.

03

What to watch

Potential reimbursement expansions for NanoKnife and cost savings from Costa Rica transition may improve margins.

Relevance 8/10Novelty 8/10Timing: today

Background

AngioDynamics is executing a transformation shifting revenue toward higher-margin MedTech products.

Company-level read

Ticker impact

$ANGONeutralHigh confidence
Context

AngioDynamics provided Q1 2027 earnings call details and new full-year revenue guidance of $336M-$341M.

Expected impact

likely modest pressure as investors weigh mixed growth signals and capital sales volatility

Evidence & confidence

New guidance and segment performance are primary disclosures; traders can adjust positions based on the outlook.

Market effects

Sector

MedTech growth may benefit related device makers, while flat MedDevice segment could pressure peers.

Regional

U.S. medtech sector sees mixed signals; no immediate global ripple.

Global

Limited to healthcare device niche.

Counterpoint

What could challenge this read

Guidance could be a floor; upside potential if MedTech growth exceeds 15% and capital sales stabilize.

Key entities

  • Executive
    Eric Honer

    New President and CEO effective November 2.

  • Product
    NanoKnife

    Device transitioning to primary prostate care tool with BPH study.

Read at source← All news

Also covered by

5 outlets

Related articles

OCT 8
$ANGOHigh

Why AngioDynamics Crashed Today

AngioDynamics (ANGO) shares fell 20.7% despite beating Q1 earnings estimates. The company reported a $0.04 per share pro forma loss, but a $0.17 GAAP loss. Revenue grew 6.9% year-over-year. Eric Honroth was named CEO, succeeding Jim Clemmer. The company has not been profitable since 2020 and is not expected to be until 2029, according to analysts.

finance.yahoo.com2 min
OCT 8
$ANGOMed

AngioDynamics Q1 Earnings Call Highlights

AngioDynamics (ANGO) reported Q1 revenue growth in NanoKnife, up 29% to $8.3M, with probe sales rising 24.1% and capital sales up 53.5%. The company expects AlphaReturn to expand its product line. Gross margin improved to 59.4%, and adjusted EBITDA increased to $5M. The company reaffirmed its fiscal 2027 outlook, expecting revenue of $336M-$341M and adjusted EBITDA of $13M-$16M.

finance.yahoo.com2 min
OCT 8
$ANGOHighAI 8/10

AngioDynamics Q1 FY2027 net loss narrows to $7.1M

AngioDynamics (NASDAQ: ANGO) reported Q1 FY2027 net loss of $7.1M, down from $10.9M YoY. Net sales rose 6.9% to $80.9M, with Med Tech sales up 13.2%. Adjusted EBITDA was $5.0M. The company announced Eric Honroth as new CEO, effective November 2, 2026. FDA approved IDE for RELIEF study on NanoKnife IRE for benign prostatic hyperplasia. Guidance reiterated: net sales $336M-$341M, adjusted EBITDA $13M-$16M.

stocktitan.net2 min